Determining the frequency of serious adverse reactions of inactive SARS-COV-2 vaccine

dc.contributor.authorKaya, Ferit
dc.contributor.authorPirincci, Edibe
dc.date.accessioned2026-08-12T17:19:44Z
dc.date.issued2021
dc.departmentFırat Üniversitesi
dc.description.abstractBACKGROUND: Vaccines are a new combat strategy against COVID-19. The success of a large number of vaccines and the continued development of vaccines will change the course of the current pandemic. OBJECTIVE: The aim of the study was to determine the frequency of serious adverse reactions caused by the administration of inactive vaccine administration on healthcare workers during the COVID-19 pandemic. METHODS: The prospective study was conducted among healthcare professionals working in city a Training and Research Hospital and applied to have the second dose of CoronaVac vaccine. The number of personnel included in the study were 329. The data were recorded in the SPSS 23 program and the chi-square test was used for statistical analysis. RESULTS: The average age of the participants in the study was 35.77 +/- 9.07. Of the participants, 28.1% were physicians. The frequency ratio of those who stated that they had serious adverse reactions after vaccination was 33.2%. Three most common systemic serious adverse reactions were headache, state of sleep/fatigue, and nausea and vomiting respectively. Serious adverse reactions occurred within 1.14 +/- 04 days after vaccine administration. The average duration of serious adverse reactions was determined as 1.68 +/- 0.77 days. 62.2% of the participants with serious side effects were women (p < 0.001). Of the participants who had serious adverse reactions, 77.5% were health care professionals (p < 0.01). CONCLUSION: No life-threatening serious adverse reactionwas determined regarding the CoronaVac vaccine administered in this study. However, local serious adverse reactions, nausea/vomiting, fever and sleepiness/fatigue occurred frequently. Further studies are required on the newly introduced vaccine.
dc.identifier.doi10.3233/WOR-210473
dc.identifier.endpage739
dc.identifier.issn1051-9815
dc.identifier.issn1875-9270
dc.identifier.issue3
dc.identifier.pmid34219684
dc.identifier.scopus2-s2.0-85111128445
dc.identifier.scopusqualityQ2
dc.identifier.startpage735
dc.identifier.urihttps://doi.org/10.3233/WOR-210473
dc.identifier.urihttps://hdl.handle.net/11508/53304
dc.identifier.volume69
dc.identifier.wosWOS:000675529800004
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSage Publications Inc
dc.relation.ispartofWork-A Journal of Prevention Assessment & Rehabilitation
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260511
dc.subjectPandemic
dc.subjecthealthcare professionals
dc.subjectfever
dc.subjectinjection site
dc.subjecthospital
dc.subjectCOVID-19
dc.titleDetermining the frequency of serious adverse reactions of inactive SARS-COV-2 vaccine
dc.typeArticle

Dosyalar